Cargando…

Clinical use of nintedanib in patients with idiopathic pulmonary fibrosis

Idiopathic pulmonary fibrosis (IPF) is a rare lung disease characterised by progressive loss of lung function, dyspnoea and cough. IPF has a variable clinical course but a poor prognosis. Nintedanib, a tyrosine kinase inhibitor, is one of two drugs approved for the treatment of IPF. In clinical tria...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hajari Case, Amy, Johnson, Peace
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2017
Materias:	Interstitial Lung Disease
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5531305/ https://www.ncbi.nlm.nih.gov/pubmed/28883926 http://dx.doi.org/10.1136/bmjresp-2017-000192

Ejemplares similares

Nintedanib in patients with idiopathic pulmonary fibrosis and preserved lung volume
por: Kolb, Martin, et al.
Publicado: (2017)

Safety and survival data in patients with idiopathic pulmonary fibrosis treated with nintedanib: pooled data from six clinical trials
por: Lancaster, Lisa, et al.
Publicado: (2019)

Effect of statins on disease-related outcomes in patients with idiopathic pulmonary fibrosis
por: Kreuter, Michael, et al.
Publicado: (2017)

Metabolic heterogeneity of idiopathic pulmonary fibrosis: a metabolomic study
por: Zhao, Yidan D, et al.
Publicado: (2017)

Time to diagnosis of idiopathic pulmonary fibrosis in the IPF-PRO Registry
por: Snyder, Laurie D, et al.
Publicado: (2020)

In-Hospital Mortality in Patients with Idiopathic Pulmonary Fibrosis: A US Cohort Study
por: Durheim, Michael T., et al.
Publicado: (2019)

Safety of pirfenidone in patients with idiopathic pulmonary fibrosis: integrated analysis of cumulative data from 5 clinical trials
por: Lancaster, Lisa, et al.
Publicado: (2016)

Neutrophil lymphocyte ratio as an indicator for disease progression in Idiopathic Pulmonary Fibrosis
por: Achaiah, Andrew, et al.
Publicado: (2022)

Cluster analysis of transcriptomic datasets to identify endotypes of idiopathic pulmonary fibrosis
por: Kraven, Luke M, et al.
Publicado: (2023)

Topological data analysis identifies molecular phenotypes of idiopathic pulmonary fibrosis
por: Shapanis, Andrew, et al.
Publicado: (2023)

National data on prevalence of idiopathic pulmonary fibrosis and antifibrotic drug use in Finnish specialised care
por: Salonen, Johanna, et al.
Publicado: (2022)

Antineutrophil cytoplasmic antibody-positive conversion and microscopic polyangiitis development in patients with idiopathic pulmonary fibrosis
por: Kagiyama, Naho, et al.
Publicado: (2015)

Serial CT analysis in idiopathic pulmonary fibrosis: comparison of visual features that determine patient outcome
por: Jacob, Joseph, et al.
Publicado: (2020)

Self-reported Gastrointestinal Side Effects of Antifibrotic Drugs in Dutch Idiopathic Pulmonary Fibrosis patients
por: Proesmans, V. L. J., et al.
Publicado: (2019)

A qualitative study of informal caregivers’ perspectives on the effects of idiopathic pulmonary fibrosis
por: Belkin, Amanda, et al.
Publicado: (2014)

Rationale for and design of the Idiopathic Pulmonary Fibrosis–PRospective Outcomes (IPF-PRO) registry
por: O'Brien, Emily C, et al.
Publicado: (2016)

Gene correlation network analysis to identify regulatory factors in idiopathic pulmonary fibrosis
por: McDonough, John E, et al.
Publicado: (2019)

Central lung gene expression associates with myofibroblast features in idiopathic pulmonary fibrosis
por: Huang, Yong, et al.
Publicado: (2023)

Baseline clinical characteristics, comorbidities and prescribed medication in a real-world population of patients with idiopathic pulmonary fibrosis: the PROOF registry
por: Wuyts, Wim A, et al.
Publicado: (2018)

Quantification of pulmonary perfusion in idiopathic pulmonary fibrosis with first pass dynamic contrast-enhanced perfusion MRI
por: Weatherley, Nicholas D, et al.
Publicado: (2021)

Sequencing of idiopathic pulmonary fibrosis-related genes reveals independent single gene associations
por: Coghlan, Meghan A, et al.
Publicado: (2014)

Randomised, double-blind, placebo-controlled pilot trial of omeprazole in idiopathic pulmonary fibrosis
por: Dutta, Prosenjit, et al.
Publicado: (2019)

Connective tissue disease related interstitial lung diseases and idiopathic pulmonary fibrosis: provisional core sets of domains and instruments for use in clinical trials
por: Saketkoo, Lesley Ann, et al.
Publicado: (2014)

Psychometric properties of the St George’s Respiratory Questionnaire in patients with idiopathic pulmonary fibrosis: insights from the INPULSIS trials
por: Swigris, Jeffrey J, et al.
Publicado: (2018)

Randomised clinical trial of an early palliative care intervention (SUPPORT) for patients with idiopathic pulmonary fibrosis (IPF) and their caregivers: protocol and key design considerations
por: Lindell, Kathleen Oare, et al.
Publicado: (2018)

Patients with idiopathic pulmonary fibrosis have poor clinical outcomes with COVID-19 disease: a propensity matched multicentre research network analysis
por: Naqvi, Syeda Fatima, et al.
Publicado: (2021)

Acute exacerbation of idiopathic pulmonary fibrosis: a 10-year single-centre retrospective study
por: Yamazoe, Masatoshi, et al.
Publicado: (2018)

Real-world retrospective observational study exploring the effectiveness and safety of antifibrotics in idiopathic pulmonary fibrosis
por: Wright, William Alexander, et al.
Publicado: (2021)

Correlation of respiratory oscillometry with CT image analysis in a prospective cohort of idiopathic pulmonary fibrosis
por: Wu, Joyce K Y, et al.
Publicado: (2022)

Gremlin-1 for the Differential Diagnosis of Idiopathic Pulmonary Fibrosis Versus Other Interstitial Lung Diseases: A Clinical and Pathophysiological Analysis
por: Aoshima, Yoichiro, et al.
Publicado: (2021)

Study design and rationale for the TETON phase 3, randomised, controlled clinical trials of inhaled treprostinil in the treatment of idiopathic pulmonary fibrosis
por: Nathan, Steven D, et al.
Publicado: (2022)

Relationship between body composition, exercise capacity and health-related quality of life in idiopathic pulmonary fibrosis
por: Machado, Felipe V C, et al.
Publicado: (2021)

Fine crackles on chest auscultation in the early diagnosis of idiopathic pulmonary fibrosis: a prospective cohort study
por: Moran-Mendoza, Onofre, et al.
Publicado: (2021)

Survival and acute exacerbation for patients with idiopathic pulmonary fibrosis (IPF) or non-IPF idiopathic interstitial pneumonias: 5-year follow-up analysis of a prospective multi-institutional patient registry
por: Tsubouchi, Kazuya, et al.
Publicado: (2023)

Investigating the effects of nintedanib on biomarkers of extracellular matrix turnover in patients with IPF: design of the randomised placebo-controlled INMARK®trial
por: Maher, Toby M, et al.
Publicado: (2018)

Characteristics of lung cancer in idiopathic pulmonary fibrosis with single lung transplant versus non-transplanted patients: a retrospective observational study
por: Gershman, Evgeni, et al.
Publicado: (2020)

Hospital-level variation in practices and outcomes for patients with severe acute exacerbations of idiopathic pulmonary fibrosis: a retrospective multicentre cohort study
por: Shankar, Divya A, et al.
Publicado: (2023)

Inhibition of mast cells: a novel mechanism by which nintedanib may elicit anti-fibrotic effects
por: Overed-Sayer, Catherine, et al.
Publicado: (2020)

Derivation and validation of a simple multidimensional index incorporating exercise capacity parameters for survival prediction in idiopathic pulmonary fibrosis
por: Chandel, Abhimanyu, et al.
Publicado: (2023)

Effect of continued treatment with pirfenidone following clinically meaningful declines in forced vital capacity: analysis of data from three phase 3 trials in patients with idiopathic pulmonary fibrosis
por: Nathan, Steven D, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_v5gqk5oul0cmr9u2ir08r28cfc